Javascript must be enabled to continue!
Project HALO: A Post-Market, Observational Registry of Data Derived from Serenity LiquidTM, Serenity GenomeTM, and Clinical Parameters (Preprint)
View through CrossRef
BACKGROUND
Registries are a valuable tool for data collection and observation of medical innovations in a real-world setting. Serenity LiquidTM and Serenity GenomeTM are newly launched diagnostic platforms analyzing large genetic datasets in combination with clinical data to deliver precision preventative medicine. To this point, no systematic data is available to observe the use and clinical implementations of these platforms.
OBJECTIVE
To create a data repository collecting data from Serenity LiquidTM, Serenity GenomeTM, and clinical parameters for analyses.
METHODS
Individuals receiving Serenity LiquidTM or Serenity GenomeTM are solicited to participate in this registry. In addition to the initial dataset, a clinical update is secured every six months. Data from the registry participants are pseudo-anonymized and archived in a HIPPA-compliant research database for regular analyses.
RESULTS
Includes but is not limited to correlations between genetic and clinical data, the impact of genetic data on the clinical course of patients, comparisons between specific cohorts (within this database and against historical cohorts) on an ongoing basis.
CONCLUSIONS
This is a prospective registry collecting genetic and clinical data to gather important information, provide novel insights by continuously analyzing the data in this registry.
JMIR Publications Inc.
Title: Project HALO: A Post-Market, Observational Registry of Data Derived from Serenity LiquidTM, Serenity GenomeTM, and Clinical Parameters (Preprint)
Description:
BACKGROUND
Registries are a valuable tool for data collection and observation of medical innovations in a real-world setting.
Serenity LiquidTM and Serenity GenomeTM are newly launched diagnostic platforms analyzing large genetic datasets in combination with clinical data to deliver precision preventative medicine.
To this point, no systematic data is available to observe the use and clinical implementations of these platforms.
OBJECTIVE
To create a data repository collecting data from Serenity LiquidTM, Serenity GenomeTM, and clinical parameters for analyses.
METHODS
Individuals receiving Serenity LiquidTM or Serenity GenomeTM are solicited to participate in this registry.
In addition to the initial dataset, a clinical update is secured every six months.
Data from the registry participants are pseudo-anonymized and archived in a HIPPA-compliant research database for regular analyses.
RESULTS
Includes but is not limited to correlations between genetic and clinical data, the impact of genetic data on the clinical course of patients, comparisons between specific cohorts (within this database and against historical cohorts) on an ongoing basis.
CONCLUSIONS
This is a prospective registry collecting genetic and clinical data to gather important information, provide novel insights by continuously analyzing the data in this registry.
Related Results
P-046 Effect of different sperm chromatin dispersion type on IVF/ICSI outcome and offspring profile
P-046 Effect of different sperm chromatin dispersion type on IVF/ICSI outcome and offspring profile
Abstract
Study question
Whether the percentage of different sperm chromatin dispersion type are associated with the IVF/ICSI out...
Dexmedetomidine Orally Dissolving Film for Acute Agitation Associated with Schizophrenia or Bipolar Disorder: SERENITY I and SERENITY II Trials
Dexmedetomidine Orally Dissolving Film for Acute Agitation Associated with Schizophrenia or Bipolar Disorder: SERENITY I and SERENITY II Trials
AbstractEpisodes of acute agitation associated with psychiatric disorders are often managed in emergency and inpatient settings. These trials evaluated the efficacy, safety, and to...
Abstract OT-11-01: The informed genetics annotated patient registry: The iGAP registry
Abstract OT-11-01: The informed genetics annotated patient registry: The iGAP registry
Abstract
Background
Interest and knowledge about the genetics and biology of inherited risk of and progression of disease is growing. Physicians are i...
The state of cancer care in Russia. Analytical indicators: one-year mortality (population study at the federal district level)
The state of cancer care in Russia. Analytical indicators: one-year mortality (population study at the federal district level)
In February 2019, Russia's first Population-based Cancer Registry (PCR) was created at the federal district level with a database of more than 1 million 350 thousand obser...
Registry-Based Randomized Controlled Trials: Conduct, Advantages and Challenges – A Systematic Review.
Registry-Based Randomized Controlled Trials: Conduct, Advantages and Challenges – A Systematic Review.
Abstract
Background: Registry-based Randomized Controlled Trials (rRCTs) have been described as pragmatic studies utilising patient data embedded in large scale registries,...
Registry-based randomised controlled trials: conduct, advantages and challenges—a systematic review
Registry-based randomised controlled trials: conduct, advantages and challenges—a systematic review
Abstract
Background
Registry-based randomised controlled trials (rRCTs) have been described as pragmatic studies utilising patient data embedded in ...
Assessment and comparison of probability scores to predict giant cell arteritis
Assessment and comparison of probability scores to predict giant cell arteritis
Abstract
Introduction/objectives
To assess and compare the performance of the giant cell arteritis probability score (GCAPS), Ing score, Bhavsar-Kha...
Abstract PO-209: Overcoming challenges through an academic-community health center collaborative to conduct cancer screening, prevention, & control among Asian Americans and sustainability initatives
Abstract PO-209: Overcoming challenges through an academic-community health center collaborative to conduct cancer screening, prevention, & control among Asian Americans and sustainability initatives
Abstract
The purpose of this presentation is to report accomplishments of a 3-year [5/1/2018-4/30/2021] Bristol-Meyers Squibb Foundation-funded collaboration between...

